Tarsus Pharmaceuticals, Inc. has purchased iRenix Medical Inc. and its investigational ocular antiseptic designed to reduce post-procedural pain and corneal toxicity.
First, let’s talk about this deal.
Tarsus shared two monetary details surrounding the transaction; it involves an upfront amount of an estimated $75 million, broken down to:
- $37.5 million in cash
- $37.5 million in Tarsus common stock
And regarding that investigational asset: Pending a potential FDA approval, its commercial milestone payments will be up to $490 million.
Impressive. Now to the focus of this acquisition: iRenix.
Headquartered in Palo Alto, California, iRenix is a privately-held, clinical-stage ophthalmic company that was founded in 2016 with an initial focus of commercializing an applicator for cryo-anesthesia and analgesia.
- Its cofounders include current CEO Stephen Smith, MD, and Cagri Besirli, MD, associate professor of ophthalmology at the University of Michigan (U of M).
- Also worth noting: The company’s original technology was part of a 2017 license agreement with the U of M (see here for those details).
And since then?
The company has pivoted to advancing and leveraging premium drug-delivery technology to target unmet needs within the intravitreal (IVT) injection space.
Specifically: Addressing the need for safer, more efficacious ocular antisepsis during intraocular procedures by advancing an alternative to povidone iodine (Betadine) for use prior to IVT injections.
Expand more on this need for a replacement.
For some context on this: Povidine iodine (PVP-I) is an over-the-counter (OTC) medication that functions as an antiseptic to kill germs on the skin (via topical application) as well as to prevent skin infections.
In ophthalmic context: It’s considered a gold-standard antiseptic for intraocular surgeries, such as cataract procedures and IVT injections.
- And in practice: Surgeons typically apply a 5% solution to the conjunctival fornix and eyelid margins for preoperative preparation to prevent potentially infections, such as endophthalmitis.
However, PVP-I is also associated with significant ocular toxicity that may lead to corneal damage and persistent pain following treatment.
Which patients may be at risk for this?
Largely those with chronic retinal diseases—wet age-related macular degeneration (AMD), diabetic macular edema (DME), retinal vein occlusion (RVO)-related macular edema, and geographic atrophy (GA), to name a few—who require frequent IVT injections to preserve their vision.
The issues: Such recurring frequency (which is entirely dependent on patient adherence) and continued exposure to PVP-I has also been found to lead to corneal damage and persistent pain (as mentioned earlier).
- “This may affect a patient’s willingness to return for future treatments and disrupt continuity of care,” Tarsus noted.
And iRenix’s candidate is designed to avoid this risk?
Indeed. IRX-101 is an investigational ocular antiseptic based on a stable aqueous chlorine dioxide solution
- Its purpose: To reduce post-procedural pain, irritation, and corneal toxicity in patients receiving IVT therapy.
How it works: By specifically targeting the bacterial cell wall—a contrast to PVP-I, which is nonspecific with a broader toxic mechanism.
Let’s talk about its clinical performance thus far.
Starting with preclinical data: IRX-101 was reportedly successful in completely killing two Gram-positive bacteria (Staphylococcus epidermidis and S. aureus, both which can lead to serious eye infections) in 15 to 30 seconds.
- Comparatively: PVP-I failed to reach such levels within even 2 minutes of exposure to the bacteria.
And more recently?
Data from the randomized, double-masked phase 2b/3 SteRilizing Eye SoLution to ImprovE Patient ComFort (RELIEF) trial were presented during last year’s American Society of Retina Specialists (ASRS).
Some details:
- The study (NCT05747430) randomized patients (2:1) undergoing IVT injections to receive either IRX-101 or 5% PVP-I.
- A total of 155 participants (aged 18+) were enrolled (inclusion and exclusion criteria here).
- Primary outcome was safety of the IRX-101, measured via slit lamp and fundoscopic examination (at 1-hour and 1-week post-treatment).
- Secondary outcomes included mean corneal fluorescein staining (CFS) scores and patient-reported post-injection pain scores.
- Timeframes were immediately following IVT injection and 1-hour post-administration, respectively.
So what did the data show?
The positive data found IRX-101 “demonstrated statistically significant reductions in post-procedural pain” and CFS compared to PVP-I.
Looking at pain reduction: An estimated 50% relative reduction in post-procedural pain scores (p = 0.0003)—and half of the IRX-101-treated patients reported a pain score of 0.
And for CFS: An estimated 35% relative reduction in corneal staining among patients in the IRX-101 group (reflecting less corneal surface damage, Tarsus noted).
Any other results?
Yes, as reported by other news outlets last year:
- At 1 hour post-injection, IRX-101-administered patients were more likely than those in the PVP-I group to indicate they were “happier than a previous injection.”
- A subset of patients, identified as PVP-I-sensitive, also had lower pain and CFS scores.
Definitely sounds like a positive performance … and what’s next?
With Tarsus now assuming ownership over IRX-101 and its clinical investigations, the company plans to initiate a phase 3 study to evaluate its tolerability and safety versus PVP-I.
This trial will kick off in alignment with feedback from the FDA and based on those phase 2b results, Tarsus added.
Any other details on its design yet?
Nothing to report from the company itself; however, we did locate this Clinical Trials page for a phase 3 trial estimated to kick off in September 2026 (with a December 2027 completion date).
- While not confirmed by Tarsus, the study page indicates this randomized, double-masked study (dubbed COMFORT) will evaluate the safety and tolerability of IRX-101 versus 5% PVP-1 among patients receiving IVT injections.
Interesting …
Very. However, the timeframe for that COMFORT trial doesn’t quite add up with Tarsus announcing plans to begin patient enrollment for its phase 3 trial in H1 2027—and results anticipated by 2028.
As always, stay tuned for updates on this front.